Citations

Showing 10 of 108094 citations.

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Mathis, Kellie L. , Tse, Chung Sang , Pembérton, John H., Shen, Bo , Kochhar, Gursimran , Singh, Amandeep , Dulai, Parambir S. , Eisenstein, Samuel , Sandborn, William J. , Parry, Lisa, Stringfield, Sarah , Hudesman, David , Remzi, Feza H. , Loftus, Edward V. , Tse, C S , Loftus, Edward V , Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | March 2, 2018 | Volume: 24 | Issue: 4 | Pages: 871-876

10.1093/ibd/izx076 | PMID 29509927 Get It

Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival
Rayfield, Corbin, Grady, Fillan S. , León, Gustavo De , Rockne, Russell C. , Jackson, Pamela , Vora, Mayur, Johnston, Sandra K. , Clark-Swanson, Kamala , Whitmire, Scott A., Gamez, Mauricio E. , Porter, Alyx B. , Hu, Leland , Gonzalez‐Cuyar, Luis F. , Vora, Sujay A., Swanson, Kristin R. , Rayfield, Corbin A, Grady, Fillan, De Leon, Gustavo, Rockne, Russell, Carrasco, Eduardo, Hawkins-Daarud, Andrea, Clark-Swanson, Kamala R., Whitmire, Scott, Porter, Alyx, Gonzalez-Cuyar, Luis, Vora, Sujay, Swanson, Kristin R , Carrasco, Eduardo , Hawkins‐Daarud, Andrea , Bendok, Bernard R.

Mayo Clinic

JCO Clinical Cancer Informatics | March 1, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-14

10.1200/cci.17.00080 | PMID 30652553 Get It

PurposeDespite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on the underlying cause of the differences in patient survivals. Serial imaging assessment of tumor growth allows quantification of tumor growth kinetics (TGK) measured in terms of changes in the velocity of radial expansion seen on imaging. Because a systematic study of this entire TGK phenotype—growth before treatment and during each treatment to recurrence —has never been coordinately studied in GBMs, we sought to identify whether patients cluster into discrete groups on the basis of their TGK.Patients and MethodsFrom our multi-institutional database, we identified 48 patients who underwent maximally safe resection followed by radiotherapy with imaging follow-up through the time of recurrence. The patients were then clustered into two groups through a k-means algorithm taking as input only the TGK before and during treatment.ResultsThere was a significant survival difference between the clusters ( P = .003). Paradoxically, patients among the long-lived cluster had significantly larger tumors at diagnosis ( P = .027) and faster growth before treatment ( P = .003) but demonstrated a better response to adjuvant chemotherapy ( P = .048). A predictive model was built to identify which cluster patients would likely fall into on the basis of information that would be available to clinicians immediately after radiotherapy (accuracy, 90.3%).ConclusionDichotomizing the heterogeneity of GBMs into two populations—one faster growing yet more responsive with increased survival and one slower growing yet less responsive with shorter survival—suggests that many patients who receive standard-of-care treatments may get better benefit from select alternative treatments.
Toward a normalized clinical drug knowledge base in China—applying the RxNorm model to Chinese clinical drugs
Wang, Li , Zhang, Yaoyun , Jiang, Min , Dong, Jiancheng , Liu, Yun , Tao, Cui , Jiang, Guoqian , Zhou, Yi , Xu, Hua , Tao, Cui , Wang, Jingqi

Mayo Clinic

Journal of the American Medical Informatics Association | March 1, 2018 | Volume: 25 | Issue: 7 | Pages: 809-818

10.1093/jamia/ocy020 | PMID 29635469 Get It

Abstract Objective In recent years, electronic health record systems have been widely implemented in China, making clinical data available electronically. However, little effort has been devoted to making drug information exchangeable among these systems. This study aimed to build a Normalized Chinese Clinical Drug (NCCD) knowledge base, by applying and extending the information model of RxNorm to Chinese clinical drugs. Methods Chinese drugs were collected from 4 major resources—China Food and Drug Administration, China Health Insurance Systems, Hospital Pharmacy Systems, and China Pharmacopoeia—for integration and normalization in NCCD. Chemical drugs were normalized using the information model in RxNorm without much change. Chinese patent drugs (i.e., Chinese herbal extracts), however, were represented using an expanded RxNorm model to incorporate the unique characteristics of these drugs. A hybrid approach combining automated natural language processing technologies and manual review by domain experts was then applied to drug attribute extraction, normalization, and further generation of drug names at different specification levels. Lastly, we reported the statistics of NCCD, as well as the evaluation results using several sets of randomly selected Chinese drugs. Results The current version of NCCD contains 16 976 chemical drugs and 2663 Chinese patent medicines, resulting in 19 639 clinical drugs, 250 267 unique concepts, and 2 602 760 relations. By manual review of 1700 chemical drugs and 250 Chinese patent drugs randomly selected from NCCD (about 10%), we showed that the hybrid approach could achieve an accuracy of 98.60% for drug name extraction and normalization. Using a collection of 500 chemical drugs and 500 Chinese patent drugs from other resources, we showed that NCCD achieved coverages of 97.0% and 90.0% for chemical drugs and Chinese patent drugs, respectively. Conclusion Evaluation results demonstrated the potential to improve interoperability across various electronic drug systems in China.
Efficacy and Outcomes of Intrathecal Analgesia as Part of an Enhanced Recovery Pathway in Colon and Rectal Surgical Patients
Merchea, Amit , Lovely, Jenna K. , Jacob, Adam K. , Mathis, Kellie L. , Spears, Grant M. , Colibaseanu, Dorin T, Kelley, Scott R. , Colibaseanu, Dorin , Huebner, Marianne , Larson, David W.

Mayo Clinic

Surgery Research and Practice | March 1, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/8174579 | PMID 29687077 Get It

Purpose. Multimodal analgesia is an essential component of an enhanced recovery pathway (ERP). An ERP that includes the use of single-injection intrathecal analgesia (IA) has been shown to decrease morbidity and cost and shorten length of stay (LOS). Limited data exist on safety, feasibility, and the optimal IA regimen. Our objective was to characterize the efficacy, safety, and feasibility of IA within an ERP in a cohort of colorectal surgical patients. Methods. We performed a retrospective review of all consecutive patients aged ≥ 18 years who underwent open or minimally invasive colorectal surgery from October 2012 to December 2013. All patients were enrolled in an institutional ERP that included the use of single-injection IA. Demographics, anesthetic management, efficacy (pain scores and opiate consumption), postoperative ileus (POI), adverse effects, and LOS are reported. Results. 601 patients were identified. The majority received opioid-only IA (91%) rather than a multimodal regimen. Median LOS was 3 days. Overall rate of ileus was 16%. Median pain scores at 4, 8, 16, 24, and 48 hours were 3, 2, 3, 4, and 3, respectively. There was no difference in postoperative pain scores, LOS, or POI based on intrathecal medication or dose received. Overall, development of respiratory depression (0.2%) or pruritus (1.2%) was rare. One patient required blood patch for postdural headache. Conclusion. Intrathecal analgesia is safe, feasible, and efficacious in the setting of ERP for colorectal surgery. All regimens and doses achieved a short LOS, low pain scores, and a low incidence of POI. This trial is registered with Clinicaltrails.gov NCT03411109.
A169 EFFICACY AND SAFETY OF ELUXADOLINE IN ELDERLY PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA
Lacy, B, Harris, Lucinda A. , Lucak, Susan, Gutman, Catherine R., Dove, Leonard S., Covington, Paul S., Chang, Lin , Lembo, Anthony

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_2 | Pages: 252-253

10.1093/jcag/gwy009.169 Get It

A279 THE EFFECT OF SHAM FEEDING ON SMALL BOWEL TRANSIT TIME IN PATIENTS UNDERGOING CAPSULE ENDOSCOPY
Ou, George , Prichard, David O. , Galorport, Cherry , Enns, Robert

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_1 | Pages: 484-485

10.1093/jcag/gwy008.280 Get It

A13 PROTEOLYTIC BACTERIA PROMOTE INNATE IMMUNE ACTIVATION AND GLUTEN-INDUCED PATHOLOGY IN MICE.
Fernandez, A Caminero, Bernier, Suzanne M., Blanco, Jorge, Galipeau, Heather J. , Fernández, Alberto Caminero, McCarville, Justin L. , Murray, Joseph A. , Surette, M G , Verdú, Elena F.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_1 | Pages: 23-24

10.1093/jcag/gwy008.014 Get It

Lesion modeling, characterization, and visualization for image-guided cardiac ablation therapy monitoring
Linte, Cristian A. , Camp, Jon J. , Rettmann, Maryam E. , Haemmerich, Dieter , Aktaş, Mehmet K. , Packer, Douglas L. , Holmes, David R. , Huang, David T.

Mayo Clinic

Journal of Medical Imaging | March 1, 2018 | Volume: 5 | Issue: 02 | Pages: 1

10.1117/1.jmi.5.2.021218 | PMID 29531966 Get It

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy
Patel, Parita , Yarur, Andrés , Dalal, Sushila , Sakuraba, Atsushi , Hanan, Ira M., Raffals, Laura H., Cohen, Russell D. , Pekow, Joel , Sakuraba, A , Rubin, David T. , Hanauer, Stephen B. , Yarur, Andres J , Pekow, Joel

Mayo Clinic

Inflammatory Bowel Diseases | March 1, 2018 | Volume: 24 | Issue: 6 | Pages: 1291-1297

10.1093/ibd/izx105 | PMID 29506124 Get It

Abstract Background IV ciclosporin therapy is effective in steroid-refractory ulcerative colitis. The optimal drug level to achieve response and minimize complications during induction therapy is not known. Aim The primary aim was to evaluate if serum ciclosporin drug levels are associated with increased risk of colectomy within 90 days of hospitalization. Secondary aims were to determine if ciclosporin levels are associated with avoidance of colectomy at 7 and 30 days, if ciclosporin levels are associated with drug-related and postoperative complications, and if patient-specific factors are associated with response to ciclosporin. Methods We conducted a retrospective analysis of 81 hospitalized patients with steroid-refractory ulcerative colitis treated with ciclosporin. Risk factors for colectomy within 7, 30, and 90 days, medication-specific and postoperative complications were compared by first, mean, and peak ciclosporin level during IV induction therapy. Results There were 47 patients (58%) who underwent surgery. There were no differences between initial, mean, and peak ciclosporin levels among responders and nonresponders and treatment-related or postoperative complications. Responders within 90 days had lower C-reactive-protein levels (20mg/L vs. 38mg/L, P = 0.01), lower serum albumin concentrations (3.4g/dL vs. 3.7g/dL, P = 0.03), and higher rates of kidney injury (50% vs 17%, P = 0.002). Conclusion Initial, mean, and peak serum levels of ciclosporin did not correlate with response or toxicity. However, C-reactive-protein levels levels and kidney injury may be helpful in predicting clinical response to ciclosporin.
Bilateral Corneal Deposits 1 Week After Starting Oral Prednisone Therapy
Starr, Matthew R. , Maguire, Leo J., Salomão, Diva R. , Starr, Matthew R

Mayo Clinic

JAMA Ophthalmology | March 1, 2018 | Volume: 136 | Issue: 5 | Pages: 591

10.1001/jamaophthalmol.2017.5316 | PMID 29494722 Get It